We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer has acquired Biohaven Pharmaceutical and its migraine drug Nurtec ODT (rimegepant sulfate), which is approved for both the prevention and treatment of episodic migraine in adults. Read More
GlaxoSmithKline (GSK) has prevailed over six other bidders with its $1.9 billion offer to purchase Sierra Oncology, gaining the Canadian company’s promising investigational Janus kinase (JAK) inhibitor, momelotinib, for the treatment of the rare blood cancer myelofibrosis. Read More
Aduhelm’s long and tortuous developmental pathway appears to have hit its final, insurmountable obstacle, with developer Biogen officially abandoning the first-ever-approved antiamyloid antibody for the treatment of Alzheimer’s disease (AD). Read More
National Cancer Institute (NCI)-designated centers are marking up oncology drugs by as much as 633 percent over the acquisition cost, according to a new cost analysis. Read More